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The endocannabinoid system (ECS) has emerged as an important regulator of both
physiological and pathological processes. Notably, this endogenous system plays a key
role in the modulation of pain and inflammation in a number of tissues. The components
of the ECS, including endocannabinoids, their cognate enzymes and cannabinoid
receptors, are localized in the eye, and evidence indicates that ECS modulation plays
a role in ocular disease states. Of these diseases, ocular inflammation presents a
significant medical problem, given that current clinical treatments can be ineffective or
are associated with intolerable side-effects. Furthermore, a prominent comorbidity of
ocular inflammation is pain, including neuropathic pain, for which therapeutic options
remain limited. Recent evidence supports the use of drugs targeting the ECS for the
treatment of ocular inflammation and pain in animal models; however, the potential for
therapeutic use of cannabinoid drugs in the eye has not been thoroughly investigated
at this time. This review will highlight evidence from experimental studies identifying
components of the ocular ECS and discuss the functional role of the ECS during different
ocular inflammatory disease states, including uveitis and corneal keratitis. Candidate
ECS targeted therapies will be discussed, drawing on experimental results obtained
from both ocular and non-ocular tissue(s), together with their potential application for
the treatment of ocular inflammation and pain.
Keywords: cannabinoids, eye, inflammation, pain, ocular inflammation, ocular pain, corneal inflammation, ocular
cannabinoids
INTRODUCTION
The ocular effects of cannabinoids have been studied extensively in animals and humans over
the last few decades. These compounds generate a number of actions in the eye including: ocular
hypotension and hyperemia, as well as modulation of visual function (reviewed in Yazulla, 2008;
Cairns et al., 2016a; Kokona et al., 2016). It was not until the 1990’s, however, that the effects of
Abbreviations: 2-AG, 2-arachidonoyl glycerol; BCEC, Bovine corneal epithelial cell; CB1R, cannabinoid 1 receptor;
CB1R−/−, cannabinoid 1 receptor knockout; CB2R, cannabinoid 2 receptor; CNS, central nervous system; DC, dendritic
cell; EAU, experimental autoimmune uveoretinitis; ECS, endocannabinoid system; EGFR, epidermal growth factor receptor;
EIU, endotoxin-induced uveitis; ERK, extracellular signal-regulated kinases; HCEC, human corneal epithelial cells; IOP,
intraocular pressure; TRPV1, transient receptor potential channel subtype 1; Vc/C1, subnucleus caudalis/upper cervical cord;
Vi/Vc, subnucleus interpolaris/ subnucleus caudalis.
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cannabinoids in the eye were formally ascribed to actions on
the ocular ECS (reviewed in Yazulla, 2008). Components of this
system, including endocannabinoid ligands that act at two cloned
cannabinoid receptors, CB1R and CB2R, and cognate enzymes
involved in endocannabinoid biosynthesis and degradation, are
present throughout ocular tissues in all species studied to date,
including humans and non-human primates (Porcella et al., 1998;
Straiker A. et al., 1999; Straiker A.J. et al., 1999; Porcella et al.,
2000; Hu et al., 2010; Bouskila et al., 2012, 2013; Cécyre et al.,
2013, 2014).
The ocular hypotensive effects of cannabinoids, specifically,
have generated considerable interest over the last few decades
largely due to their potential use in the treatment of glaucoma.
Glaucoma is a blinding eye disease characterized by a progressive
painless loss of vision, for which IOP is a primary risk factor
(reviewed in Tomida, 2004; Nucci et al., 2007; Pinar-Sueiro
et al., 2011; Cairns et al., 2016a). The IOP lowering actions of
cannabinoids arise primarily via interactions at CB1R that are
localized to anterior eye tissues involved in the production and
outflow of aqueous humor (Straiker A. et al., 1999; Straiker
A.J. et al., 1999; Hudson et al., 2011). Additional retinal
neuroprotective and decreased neuroinflammatory responses
have also been reported in the eye for cannabinoids acting at
CB1Rs (Pryce et al., 2003; Rossi et al., 2011; reviewed by Cairns
et al., 2016b).
Despite evidence for reducing IOP and potential
neuroprotective benefits, the medical community has not
embraced the use of cannabinoids as a clinical treatment for
glaucoma (Järvinen et al., 2002; Buys and Rafuse, 2010; Novack,
2016). This was documented by the Canadian Ophthalmological
Society in a full policy statement released in 2010 (Buys and
Rafuse, 2010) and by the American Academy of Ophthalmology
in Schwab et al. (2014). This is largely because the actions of
cannabinoids that act at CB1R in humans and experimental
vertebrate animals produce transient alterations in IOP,
are subject to tachyphylaxis, and can have both peripheral
and CNS side-effects (Corchero et al., 1999; Chiou et al.,
2013).
Both CB1R and CB2R mRNA and protein have been reported
in the eye (reviewed in Yazulla, 2008; Bouchard et al., 2016;
Cairns et al., 2016b). CB1R is expressed throughout the retina
and is also is found in some anterior ocular tissues, including
the trabecular meshwork (Straiker A.J. et al., 1999; Porcella
et al., 2000; Stamer et al., 2001). In contrast to broader ocular
distribution of CB1R, expression of CB2R in the eye is more
limited and largely localized to resident immune cells and retinal
glia in primates (Bouskila et al., 2013), although the CB2R has
been reported in murine retina including the retinal pigment
epithelium, photoreceptors, horizontal and amacrine cells and
within the ganglion cell layer (López et al., 2011). CB2Rs have
been implicated in aqueous humor turnover (Zhong et al.,
2005). However, unlike CB1Rs, the IOP lowering actions of
cannabinoids are still present in CB2R null animals (Hudson
et al., 2010; Caldwell et al., 2013), arguing against a role for the
use of CB2R agonists to regulate IOP. More recently, several
publications have indicated that cannabinoids targeting CB2R
may be therapeutically relevant in ocular inflammatory disease
(Xu et al., 2007; Toguri et al., 2014, 2015). Additionally, several
non-cannabinoid receptors, including GPR18 which binds the
endogenous ligand N-arachidonoyl glycine, have also been
implicated in the ocular actions of some cannabinoids (Caldwell
et al., 2013).
The following review addresses the ocular immune
response and presents recent evidence on ECS modulation
of ocular inflammation. A specific focus of this review is on
cannabinoid receptors as emerging non-steroidal targets for
ocular inflammatory disorders, including uveitis and corneal
keratitis and neuropathic pain, the latter of which lacks
satisfactory treatment options. We present recent evidence
that supports a prominent role for the CB2R as novel anti-
inflammatory target in the eye. Additionally, the potential
of targeting CB1Rs in corneal neuropathic pain is discussed,
together with considerations for future research and possible
limitations in the use of cannabinoids to treat ocular disease.
THE OCULAR IMMUNE SYSTEM
During ocular inflammation, a deregulated immune response
is detrimental to ocular tissue function and can have sight-
threatening consequences (Suttorp-Schulten and Rothova, 1996;
Dunn, 2015). The eye is a unique organ as it contains both the
peripheral and CNS components of the immune system, although
the two immune systems function by analogous mechanisms.
Similar to most other organ systems in the body, the eye is
privy to tissue resident macrophages and DCs that induce innate
immune responses. These cell populations are localized to the
cornea, iris, ciliary body, and choroid, while no immune cells are
present in the aqueous humor and lens under normal physiologic
conditions (McMenamin et al., 1994; Pouvreau et al., 1998; Li
et al., 2013). The cornea is an avascular tissue comprised of
an epithelial layer, stroma made of keratocytes and collagen
interlaced with a dense network of nerves, followed by the
endothelium (Figure 1; Marfurt et al., 2010; Shaheen et al.,
2014). Specialized DCs called Langerhans cells are located in the
corneal stroma (Akpek and Gottsch, 2003; Hamrah et al., 2003),
while in the iris, both macrophages and major histocompatibility
complex II class DCs are found in close proximity to the pupil
and near the ciliary body (McMenamin, 1997). The choroid is
highly populated with antigen presenting cells found throughout
the stromal connective tissue (McMenamin, 1997). Mast cells
have been localized in the choroid, and may play a role in
the susceptibility to the development of inflammation in some
experimental models (McMenamin, 1997).
This immune cell population is mirrored in the retina
by microglia, macrophages while DCs are found within the
connective tissue of the sclera (Eter et al., 2008; Kezic and
McMenamin, 2008; London et al., 2013). The tissue resident
populations of immune cells are outlined in Table 1. These
cellular populations in the periphery are primarily divided
between tissue resident macrophages and DCs which have
the ability to phagocytize foreign bodies, release inflammatory
mediators, recruit and present antigens to immune cells, and
induce differentiation and proliferation of other cells. Although
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FIGURE 1 | The cornea. Schematic representation of the corneal layers in a cross section.
the eye has a collection of resident immune cells acting as
sentinels and activators of the immune system, it also has a special
condition known as immune privilege.
THE IMMUNE PRIVILEGE OF THE EYE: A
COMPLICATING FACTOR
Immune privilege of the eye is a group of processes that
result in the suppression of inflammation to prevent tissue
damage and loss of sight. This is made up of intrinsic
factors including physical boundaries like the blood-aqueous
and blood retinal barriers; in addition to active factors such
as immunomodulatory proteins (Streilein et al., 2002). Active
factors which contribute to the immune privilege, include the
endogenous release of immunomodulatory factors into the
aqueous humor such as transforming growth factor-β (TGF-β),
immunoregulation via cell-to-cell contact mechanisms with
corneal endothelium and iris pigmented epithelium, and antigen
presenting cell development of antigen tolerance (Caspi, 2010;
Taylor and Kaplan, 2010; London et al., 2013; Mochizuki et al.,
2013). Together these adaptations help to maintain the ocular
microenvironment and proper ocular function.
TARGETING THE ECS TO TREAT
OCULAR INFLAMMATORY DISEASE
Inflammatory eye diseases contribute to the global incidence
of blinding eye disease, presenting a significant risk of vision
loss and blindness as well as a high medical and economic
burden on populations (Yu et al., 2011; Dunn, 2015). Collectively,
these conditions encompass both intraocular inflammation (e.g.,
uveitis, uveoretinitis, proliferative, and vitreoretinopathy), as well
as ocular surface inflammation, including corneal inflammation
and neuropathology (Akpek and Gottsch, 2003; Belmonte et al.,
2015; Dunn, 2015; Galor et al., 2015; Rosenthal and Borsook,
2015). Both the innate and adaptive immune responses can
result in detrimental, sight limiting complications, albeit through
different cellular mechanisms. Although the subset of immune
cells is fundamentally different during innate and adaptive
immunity, both result in immune cell migration, release of
inflammatory mediators and ensuing tissue damage (Streilein,
2003; Taylor, 2009; Caspi, 2010; Mochizuki, 2010). In some
instances pain is a co-morbidity of ocular inflammation. For
example in iritis, keratitis, and corneal trauma, pain can
be manifested as acute changes in nociception alone, or
more prolonged alterations can occur, leading to chronic and
neuropathic pain (Belmonte et al., 2015; Galor et al., 2015;
Rosenthal and Borsook, 2015; Goyal and Hamrah, 2016).
Recent evidence suggests that the ECS could be a therapeutic
target in the treatment of ocular inflammation. The effects
of cannabinoids have been shown to be beneficial in several
animal models of intraocular inflammation (Xu et al., 2007;
Altinsoy et al., 2011; Toguri et al., 2014, 2015). These studies
have included models of EIU in rabbit (Altinsoy et al., 2011),
rat (Toguri et al., 2014, 2015), and EAU in mouse (Xu et al.,
2007). Uveitis is an overarching term which typically describes
inflammation of any part of the uvea (iris, ciliary body, and
choroid). Inflammation can be strictly localized to uveal tissue or
be more extensive and involve ocular structures including: sclera,
retina, vitreous, and optic nerve (Jabs et al., 2005; Read, 2006;
Larson et al., 2011). Anterior uveitis, is additionally associated
with pain and photophobia (Smith et al., 1998; Dunn, 2015). EIU
is the most commonly used model of intraocular inflammation
and changes reported in this model are consistent with uveitis
seen in humans, including release of inflammatory mediators,
activation and recruitment of immune cells (specifically T-cells
in EAU), disruption of the blood aqueous/ blood retinal barrier,
vasculitis and granulomas (Streilein et al., 2002; Caspi, 2006;
Taylor, 2009). EAU, a widely used animal model of uveoretinitis
(posterior uveitis) (Caspi, 2006), is a specific form of uveitis
associated with chronic autoimmune disorders and affects the
retina.
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TABLE 1 | Presence and location of ocular immune cells during non-pathological conditions.
Cornea Iris Ciliary body Trabecular
meshwork
Choroid Retina Conjunctiva
Macrophages XM,R,H,G (Rodrigues
et al., 1981)
(Brissette-Storkus
et al., 2002)
(Hamrah et al.,
2003)
XM,R, (McMenamin
et al., 1994;
McMenamin, 1997)
XM,R,H
(McMenamin et al.,
1994; McMenamin,
1997)
XM,R,H
(McMenamin et al.,
1994; McMenamin,
1997)
XH (Hingorani et al.,
1997)
Dendritic cells XM (Hamrah et al.,
2002)H
(Vantrappen et al.,
1985) (Hamrah
et al., 2003)
XM,R (McMenamin,
1997)
XM,R (McMenamin,
1997)
XM,R (McMenamin,
1997)
XH (Hingorani et al.,
1997)
Mast cells X+D,Ca,Ma,H
(McMenamin,
1997)
XH (McMenamin,
1997)
XR,H (McMenamin,
1997)
X H
CD4+ T cells XH 1∗11 XH (Hingorani et al.,
1997)
CD8+ T cells XH∗(Vantrappen
et al., 1985)
XH (Hingorani et al.,
1997)
CD3+ T cell XH ∗(Vantrappen
et al., 1985)
XH (Hingorani et al.,
1997)
Monocytes XH,Mo (Alvarado
et al., 2010)
Microglia XM, R,C
(McMenamin,
1997; Langmann,
2007) (Karlstetter
et al., 2010)
Mmouse, Rrat, Hhuman, Gguinea pig, Cchick, Cacat, Momonkey, Mamarsupial, Ddog.
The first study describing the use of cannabinoids for the
treatment of intraocular inflammation, was conducted by Xu
et al. (2007) in an EAU model. The selective CB2R agonist,
JWH 133, significantly decreased inflammatory cell infiltration
in the retina, reducing cellular infiltrates and granulomas in
a dose-dependent manner. The authors attributed the effects
of JWH 133 to inhibition of leukocyte migration to multiple
pro-inflammatory stimuli. CB2R activation also inhibited T cell
proliferation and associated cytokine production. JWH 133 was
able to suppress antigen presentation, as antigen presenting cells
from animals treated with the CB2R agonist inhibited T cell
proliferation following co-culture with T cells (Xu et al., 2007).
Compared to the EAU model, cannabinoid actions have
been described more extensively in EIU. In the EIU model,
cannabinoid administration has been reported to be both pro-
inflammatory (Altinsoy et al., 2011) and anti-inflammatory
(Toguri et al., 2014, 2015). In the former study, administration
of the endocannabinoid, anandamide, in a rabbit model of
EIU, significantly increased the clinical score of intraocular
inflammation and increased leukocyte counts and protein in the
aqueous humor (Altinsoy et al., 2011). Injection of AM251, a
CB1R antagonist, resulted in a complete ablation of neutrophils
within the aqueous humor, and a reduction in histopathology.
However, although AM251was able to decrease some measures
of ocular inflammation, protein was still found in the aqueous
humor and the clinical ocular inflammation score was not
altered in the presence of the CB1R antagonist. The reduction
in neutrophils in the aqueous humor was attributed to a CB1R
driven reduction in cytokines as reported in other studies (Mnich
et al., 2010).
In further support of a CB2R-mediated anti-inflammatory
action of cannabinoids in the eye, Toguri et al. (2014)
demonstrated that topical application of the CB2R agonist,
HU308, decreased ocular inflammation in a rat EIU model.
Activation of the CB2R reduced leukocyte-endothelial adhesion
within the iridal microcirculation following LPS administration.
The decrease in leukocyte-endothelial adhesion was attributed
to the inhibition of pro-inflammatory mediators including TNF-
α, IL-1β, IL-6 as well as a reduction in the mRNA levels
of the transcription factors NF-κB and AP-1. These authors
compared the anti-inflammatory actions of the CB2R agonist,
HU308, to that of the steroids, dexamethasone and prednisolone,
and the non-steroidal anti-inflammatory drug, nepafenac, all
used clinically in the treatment of uveitis. Among these anti-
inflammatory agents, HU-308 was superior in attenuating
leukocyte-endothelial adhesion and reducing pro-inflammatory
cytokines (Toguri et al., 2014).
In further support of an anti-inflammatory action of
cannabinoids in the eye, Toguri et al. (2015) also demonstrated
that the CB1R/CB2R agonist, WIN55212-2, was able to
reduce leukocyte-endothelial adhesion within the iridial
microcirculation following systemic administration of LPS.
In this study, leukocyte adhesion was measured in vessels
with a diameter of both greater and less than 25 µm in order
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to investigate the possibility of alterations in hemodynamics
contributing to the cannabinoid effects. When only CB2Rs
were activated, in the presence of selective inhibition of
CB1Rs, leukocyte adhesion was still decreased in the iridial
microvasculature. However, when CB2Rs were blocked, allowing
only activation of CB1Rs, leukocyte adhesion was attenuated
only in smaller vessels (<25 um), a finding which was attributed
to increases in shear forces due to alterations in vascular
hemodynamics. In keeping with an improvement in iridial
microcirculatory function observed with cannabinoid treatment,
studies of ocular blood flow using Laser Doppler technology
indicated that activation of either, or both, CB1R or CB2R,
reduced the decrease in local blood flow observed when LPS was
given alone (Toguri et al., 2015).
Taken together, the majority of these studies (Xu et al., 2007;
Toguri et al., 2014, 2015) provide strong evidence that
cannabinoids, and more specifically, CB2R agonists,
are efficacious treatments for ocular inflammation, even
out-performing traditional therapies such as steroid and non-
steroidal anti-inflammatory drugs. As CB2R is upregulated
during inflammation, this receptor has potential as an
excellent drugable target for immunosuppression during
ocular inflammatory diseases.
THE ECS AND OCULAR SURFACE
INFLAMMATION AND PAIN
The corneal epithelium is densely innervated by sensory nerves
that arise from the ophthalmic division of the trigeminal nerve
(Marfurt et al., 2010; reviewed in Goyal and Hamrah, 2016).
Stimulation of corneal nociceptors by noxious stimuli activates
ion channels, such as TRPV1 channels, in sensory nerve endings
to transduce sensory information to second order neurons in
trigeminal brainstem complex before projecting via the thalamus
to somatosensory cortex and paralimbic structures (Figure 2;
reviewed in Belmonte et al., 2015; Goyal and Hamrah, 2016).
Damage to the cornea resulting from acute or chronic
infectious and non-infectious disease, or trauma, results
in the release of inflammatory mediators and immune cell
recruitment, leading to improper tissue remodeling and
peripheral sensitization. Injury-induced functional plasticity,
with alterations in the threshold potentials for peripheral corneal
nociceptors, amplifies peripheral pain signaling and can lead to
central sensitization with increased pain perception (Figure 2;
Rosenthal and Borsook, 2015; Goyal and Hamrah, 2016). Corneal
inflammatory disease (keratitis) can result in corneal neuropathy
(CNP) and is inadequately treated with current clinical agents
(reviewed in: Rosenthal and Borsook, 2012; Belmonte et al.,
2015; Galor et al., 2015; Rosenthal and Borsook, 2015; Goyal and
Hamrah, 2016).
In support for a role for the ECS in the cornea, abundant
CB1R protein is present in human and non-human primate
cornea (Straiker A.J. et al., 1999) and recent evidence indicates
mRNA for additional components of the ECS including the
endocannabinoid, 2-AG, and enzymes which metabolize
endocannabinoids such as, monoacylglycerol lipase, and
alpha/beta-hydrolase domain 6 and 12, as well as, fatty-acid
amide hydrolase and N-acylethanolamine-hydrolyzing acid
amidase (Murataeva et al., 2015). Additionally, mRNA for
G-protein coupled receptors GPR35, GPR55, and GPR92 was
also detected in bovine cornea (Murataeva et al., 2015). These
authors did not detect significant expression of CB2Rs under
non-pathological conditions.
While the literature supports the efficacy of cannabinoids that
act at both CB1Rs and CB2Rs in both acute and chronic pain,
(Guindon and Hohmann, 2008; Yu et al., 2010; La Porta et al.,
2013), the effects of cannabinoids on corneal pain specifically
have not been extensively studied. One study, however, did
investigate the effects of the non-selective CB1R/CB2R agonist,
WIN55212-2 on activity in the rat trigeminal brainstem complex;
corneal nerves terminate in two spatially distinct regions of the
medulla, the trigeminal interpolaris/caudalis (Vi/Vc) transition
and subnucleus caudalis/upper cervical cord (Vc/C1) junction
region (Bereiter et al., 2002). These authors used topical mustard
oil or a CO2 air puff to activate corneal nociceptors and found
that WIN55212-2 reduced neural activity in the Vi/Vc transition
but not in the Vc/C1 junction. The effects of WIN55212-2 were
reduced by the CB1R antagonist, SR141716. Bereiter et al. (2002)
concluded that CB1R activation affects the activity of corneal-
responsive neurons that terminate in the Vi/Vc transition and
preferentially contribute to homeostatic and reflexive corneal
functions, e.g., blinking and lacrimation, rather than neurons
that terminate in the Vc/C1 region and regulate sensory
discrimination components of corneal nociception. Given that
this study used only acute stimuli, further research examining the
role of the ECS in chronic models of corneal neuropathic pain is
needed to shed additional light on the functional role of the ECS
in corneal pain.
Recently, several reports have emerged that indicate
cannabinoid receptor modulation could have therapeutic
efficacy for corneal epithelial cell proliferation and migration,
effects which would be beneficial in promoting wound healing
and treating corneal neuropathic pathologies, respectively (Yang
et al., 2010, 2013; Murataeva et al., 2015). Yang et al. (2010), using
HCEC, reported that stimulation of CB1R caused transactivation
of EGFR and increases in transient intracellular [Ca2+]. EGFR
is associated with mediating corneal epithelial renewal, via
inducing cellular proliferation and migration. Furthermore, an
increase in HCEC proliferation was observed when either CB1R
or TRPV1 was activated.
In support of these findings, Yang et al. (2013) demonstrated
co-localization of CB1R and TRPV1 in the mouse corneal
epithelium. Using a corneal alkali burn model, these authors
also reported that the cannabinoid agonist, WIN55212-2,
improved wound healing and reduced stromal thickening, with
full recovery of the epithelial layer at 5 days post injury.
The immunosuppressive effects of WIN55212-2 in this study
were attributed to desensitization of TRPV1 and occurred
as a result of interactions between the CB1R and, TRPV1,
that resulted in a WIN55212-2-mediated decrease in TRPV1-
mediated phosphorylation of downstream signaling molecules
transforming growth factor-β-activated kinase (TAK1) and c-Jun
N-terminal kinase 1 (JNK1) activation, effects that were blocked
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FIGURE 2 | The ocular sensory pathway. The stroma of the cornea contains a dense network of nerve fibers expressing: mechanoreceptors, polymodal
receptors and cold receptors. Following damage to the corneal epithelium, inflammatory mediators are released and immune cells are recruited to the site of injury.
These inflammatory mediators include: cytokines, H+, ATP, adenosine, prostaglandins, leukotrienes, bradykinin, 5-HT, platelet-activating factor, histamine and
neuropeptides, all of which contribute to the alteration in nociceptive signaling by activating Transient receptor protein (TRP) channels of nociceptors, which are
responsible for nociceptor signaling (Rosenthal et al., 2009; Belmonte et al., 2015; Galor et al., 2015; Rosenthal and Borsook, 2015; Goyal and Hamrah, 2016).
These first order neurons project to the trigeminal ganglion and synapse with second order neurons in the trigeminal subnucleus caudalis before projecting to the
spinothalamic pathways and the thalamus or the periaqueductal gray (PAG). Third order neurons from the thalamus relay information to the somatosensory cortex
and paralimbic region, while those from the PAG modulate trigeminal activity (Belmonte et al., 2015; Galor et al., 2015; Rosenthal and Borsook, 2015; Goyal and
Hamrah, 2016). Activation of this pathway contributes to hyperalgesia and spontaneous pain by sensitizing corneal nociceptors. Chronic neuropathic pain results
after the initial lesion has healed and occurs due to a decreased threshold of stimulation, spontaneous depolarization of nociceptors and altered excitability of voltage
gated channels which modulate excitability of polymodal nociceptors. Reproduced and adapted with permission from Elsevier publishing group and Rosenthal et al.
(2009). Original image from Rosenthal et al. (2009).
by the CB1R antagonist, AM251. This report further indicated
that administration of WIN55212-2 improved corneal ulceration,
scarification and neovascularization compared to untreated
animals and that wound closure was prolonged in CB1R−/−
mice.
A CB1R-mediated and ERK-dependent signaling mechanism
for corneal epithelial cell migration was proposed by
Murataeva et al. (2015) who reported that WIN55212-2-
mediated chemotaxis of BCEC involved dephosphorylating of
ERK1/2 and was blocked following treatment with the CB1R
antagonist, SR141716. These authors also demonstrated that the
endocannabinoid, 2-AG, induced chemotaxis of BCEC; however,
this effect was only partially inhibited by SR141716, indicating
that the chemotactic properties of 2-AG may arise via actions
at a receptor distinct from CB1R. While this study provided
evidence for CB1R-mediated corneal epithelial cell migration,
unlike Yang et al. (2010), they failed to observe corneal epithelial
cell proliferation and instead observed that the CB1R agonist,
CP55940, antagonized the effects of EGF-mediated proliferation
(Murataeva et al., 2015). Differences reported in this study
compared to the study by Yang et al. (2013) were suggested to
be the result of cell-specific variation or off-target effects due to
the high concentration of cannabinoid drugs used. While clearly
additional research is required to resolve the role for cannabinoid
receptors in corneal epithelial cell growth and function, these
studies highlight a potential role of CB1Rs in corneal wound
healing.
CONCLUSION
Evidence to date suggests a role for the ECS in mitigating
ocular inflammation and pain. Although research in this
area is still relatively limited, the potential for developing
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novel pharmacological tools exploiting the ECS for ocular
inflammation and pain looks promising given that targeting
both the CB1R and CB2R has proven beneficial in models
of intraocular inflammation, including EAU and EIU (Xu
et al., 2007; Toguri et al., 2015). Activation of cannabinoid
receptors, specifically CB2R, results in decreases in immune
cell migration (during both innate and adaptive immune
responses), T-cell proliferation, inflammatory mediator release
and alterations in local blood flow. Furthermore, there are
indications that cannabinoids may have comparable and, in
some cases, superior efficacy and less side-effects compared to
traditional immunosuppressive therapeutics used in the clinic
(Toguri et al., 2014). In addition to an anti-inflammatory role
for cannabinoids in uveitis, this class of drugs, particularly
cannabinoids that act at CB1R, may have therapeutic relevance
for corneal surface damage and pain. However, at this time
research on corneal ECS is still in its infancy and further
investigation of the corneal ECS and the effects of cannabinoids in
models of corneal disease, including CNP, must be conducted in
order to better clarify cell and receptor targets and identify how
alterations in the ECS affect corneal function (Yang et al., 2010,
2013; Murataeva et al., 2015).
Furthermore, while topical and regional cannabinoid
therapies offer several advantages for treating ocular
inflammation and pain, it should also be noted that there are
challenges in formulation of these very lipophilic compounds for
drug delivery and their use may result in dose-dependent ocular
toxicity including hyperemia and reduction in tear production,
as well as tachyphylaxis with chronic use (Green and Roth, 1982;
Jay and Green, 1983). Future research should explore novel
cannabinoid drug combinations that maximize efficacy and limit
dose including allosteric modulators (Cairns et al., 2016b), as well
as appropriate routes of local delivery, novel drug formulations
and studies of both acute and chronic dosing in representative
models of ocular disease.
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